Howard I Rutman MD MBA, FACC
Adult Congenital Heart Disease
Assistant Clinical Professor, Medicine, Cardiology, Albert Einstein College of Medicine
Join to View Full Profile
EKG Associates111 East 210TH StreetBronx, NY 10467
Phone+1 718-405-8477
Fax+1 718-405-8476
Dr. Rutman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Einstein/Montefiore Med Ctr1986
Montefiore Medical Center/Albert Einstein College of Medicine (Montefiore)Fellowship, Cardiovascular Disease, 1984 - 1985
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1981 - 1984
Johns Hopkins University School of MedicineClass of 1981
Certifications & Licensure
NY State Medical License 1982 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Fellow (FACC) American College of Cardiology
Publications & Presentations
PubMed
- Application of the Win Ratio Method in the ENGAGE AF-TIMI 48 Trial Comparing Edoxaban With Warfarin in Patients With Atrial Fibrillation.Brian A Bergmark, Jeong-Gun Park, Rose A Hamershock, Giorgio E M Melloni, Raffaele De Caterina
Circulation. Cardiovascular Quality and Outcomes. 2024-07-01 - 90 citationsRelationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trialGiuseppe Boriani, Christian T. Ruff, Julia F Kuder, Minggao Shi, Hans Lanz
European Heart Journal. 2019-05-14 - 10 citationsStroke prevention in atrial fibrillation: Closing the gap.Sean D. Pokorney, Bernard J. Gersh, Azhar Ahmad, Sana M. Al-Khatib, Melanie Blank
American Heart Journal. 2019-04-01
Authored Content
- Clinical Events After Interruption of Anticoagulation in Patients with Atrial Fibrillation: An Analysis from the ENGAGE AF-TIMI 48 Trial☆February 2018
- Clinical Events After Interruption of Anticoagulation in Patients with Atrial Fibrillation: An Analysis from the ENGAGE AF-TIMI 48 Trial☆February 2018
Press Mentions
Chutes & Ladders—Gossamer Vet Salter-Cid Dons CSO Mantle at Flagship's New Pioneering Medicines UnitMay 14th, 2021- As Codiak Enters 'Next Phase of Growth,' Jennifer Wheler Steps into CMO Role; Mark Timney Lines up His Second CEO Opportunity After Purdue Pharma ReignMay 14th, 2021
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
